16 results
8-K
EX-2.1
INM
InMed Pharmaceuticals Inc
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
with the employment of any current or former applicant, employee, consultant, volunteer, intern or independent contractor of the Company, including, without
10-K
2021 FY
INM
InMed Pharmaceuticals Inc
24 Sep 21
Annual report
7:31am
of the second Phase I healthy volunteer study (755-102-HV). The 755-102-HV clinical trial is a randomized, double-blind, vehicle-controlled, Phase I study
10-K
2021 FY
EX-2.1
INM
InMed Pharmaceuticals Inc
24 Sep 21
Annual report
7:31am
Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant, volunteer, intern or independent
424B3
INM
InMed Pharmaceuticals Inc
22 Jul 21
Prospectus supplement
10:27am
announced initiation of enrollment of the second Phase I healthy volunteer study (755-102-HV). The 755-102-HV clinical trial is a randomized, double-blind … in accordance with a country’s requirements, clinical trial development may proceed. In addition to our recently concluded healthy volunteer treatment
424B3
2401 bzyju0e
16 Mar 21
Prospectus supplement
12:00am
8-K
EX-99.1
1l9ldapk1vwj
11 Jan 21
Regulation FD Disclosure
6:03am
424B4
2qsuaqnwaxtvb pn
13 Nov 20
Prospectus supplement with pricing info
8:52pm
S-1
8y8s4mmm61yds0se98
19 Jun 20
IPO registration
4:59pm
DRS/A
ziuy8cn8
27 May 20
Draft registration statement (amended)
12:00am
DRS
eipco45kqllb1wixohjd
13 Apr 20
Draft registration statement
12:00am
- Prev
- 1
- Next